|
FUBP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.89380000015227E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.25689999999923E-05 |
| Normal-vs-Stage2 |
7.66620000000051E-05 |
| Normal-vs-Stage3 |
8.29609999586367E-08 |
| Normal-vs-Stage4 |
7.08690000017498E-07 |
| Stage1-vs-Stage2 |
3.403800E-01 |
| Stage1-vs-Stage3 |
4.553600E-02 |
| Stage1-vs-Stage4 |
6.114100E-02 |
| Stage2-vs-Stage3 |
6.185400E-01 |
| Stage2-vs-Stage4 |
6.484200E-01 |
| Stage3-vs-Stage4 |
9.810200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.07270000005278E-07 |
| Normal-vs-AfricanAmerican |
5.831500E-02 |
| Normal-vs-Asian |
7.809800E-04 |
| Caucasian-vs-AfricanAmerican |
1.688760E-01 |
| Caucasian-vs-Asian |
6.569400E-01 |
| AfricanAmerican-vs-Asian |
3.387600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.14530000039359E-07 |
| Normal-vs-Female |
1.62810000003955E-06 |
| Male-vs-Female |
2.354400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.49770000000571E-05 |
| Normal-vs-Age(41-60Yrs) |
1.65071999999045E-05 |
| Normal-vs-Age(61-80Yrs) |
1.78710000131588E-08 |
| Normal-vs-Age(81-100Yrs) |
5.600900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.465400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.515600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.294800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.083000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.075000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.429000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.321200E-03 |
| Classical-VS-Follicular |
5.604500E-02 |
| Classical-VS-Other |
1.293620E-01 |
| Classical-VS-Normal |
1.87123999999539E-05 |
| Tall-VS-Follicular |
4.120800E-01 |
| Tall-VS-Other |
7.690600E-01 |
| Tall-VS-Normal |
2.4573000001471E-07 |
| Follicular-VS-Other |
5.957800E-01 |
| Follicular-VS-Normal |
2.16319999999381E-05 |
| Other-VS-Normal |
6.356100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.85440000028048E-07 |
| Normal-vs-N1 |
2.18289999999177E-05 |
| N0-vs-N1 |
6.032200E-01 |
|
|
